Avita Medical Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $143.1M
- Price
- $4.65
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.00%
- Volume
- 166.1K
Quote data as of 6:58 AM ET
About
AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.
Quick stats
Shares outstanding30.8M
Computed float30.0M
Float sourceUnknown
Cash runway (months)2.9
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001762303
Websitehttps://www.avitamedical.com
AI Summary
AI-generated21d agominorbullishclinical trialAVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical presented positive data from the first U.K. case series using its RECELL GO automated cell harvesting device at the British Burn Association Annual Meeting.
The study of 17 patients demonstrated successful outcomes in burn and reconstructive surgery, with investigators noting workflow benefits and reduced procedural variability compared to manual methods.
Additionally, a separate systematic review of 99 studies covering over 8,000 patients reinforced the safety and efficacy of the RECELL platform across global markets.